Consolidated Portfolio Review Corp Has $2.78 Million Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Consolidated Portfolio Review Corp lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 8.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 45,515 shares of the biopharmaceutical company’s stock after acquiring an additional 3,449 shares during the quarter. Consolidated Portfolio Review Corp’s holdings in Bristol Myers Squibb were worth $2,776,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Wealthspire Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 0.6% during the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock valued at $1,622,000 after buying an additional 170 shares in the last quarter. Bedel Financial Consulting Inc. grew its stake in Bristol Myers Squibb by 3.2% during the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company’s stock valued at $340,000 after acquiring an additional 175 shares in the last quarter. King Wealth Management Group grew its stake in Bristol Myers Squibb by 2.6% during the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company’s stock valued at $413,000 after acquiring an additional 182 shares in the last quarter. Thoroughbred Financial Services LLC lifted its position in shares of Bristol Myers Squibb by 1.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company’s stock worth $1,004,000 after purchasing an additional 190 shares in the last quarter. Finally, Marcum Wealth LLC boosted its holdings in shares of Bristol Myers Squibb by 1.0% during the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company’s stock worth $1,177,000 after purchasing an additional 193 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on BMY shares. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price objective on the stock. Argus raised shares of Bristol Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Jefferies Financial Group cut their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd. Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Finally, UBS Group reduced their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $58.00.

Insider Transactions at Bristol Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.07% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Stock Up 0.2%

BMY opened at $46.97 on Tuesday. The firm has a market cap of $95.59 billion, a P/E ratio of 17.59, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The business has a 50 day moving average price of $48.12 and a 200 day moving average price of $54.21. Bristol Myers Squibb Company has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($4.40) earnings per share. Research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.28%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.